Ponazuril
From Self-sufficiency
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
| File:Ponazuril.png | |
| Systematic (IUPAC) name | |
|---|---|
|
1-Methyl-3-[3-methyl-4-[4-(trifluoromethylsulfonyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione | |
| Clinical data | |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 69004-04-2 |
| ATC code | none |
| PubChem | CID 3050408 |
| Chemical data | |
| Formula | C18H14F3N3O6S |
| Molar mass | 457.380 g/mol[[Script error: No such module "String".]] |
Ponazuril (INN), sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona. More recently, veterinarians have been preparing a formulary version of the medication for use in small animals such as cats and dogs against coccidia, an intestinal parasite. Coccidia treatment is far shorter than treatment for EPM.
| 40x30px | This veterinary medicine–related article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Orphaned articles from February 2009
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- Veterinary medicine stubs
- Equine medications
- 2Fix
